A GENOMIC METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENTS AGAINST GLIOBLASTOMA
Patent Information
- Application Number
- IT102024000019252
- Authority / Receiving Office
- IT · IT
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2026-08-31
- Estimated Expiration
- 2044-08-26
Description
“ ’ ” ’
Claims
CLAIMS 1. A pharmaceutical composition for use in the treatment of glioblastoma of Sassoealto grades comprising as active compounds e-ketooolac, bumetanide and nifiumic acid.
2. The pharmaceutical composition for use according to claim 1, wherein the dose of each of the active substances during the combined treatment is equal to or less than 100U at the injection site.
3. The comsosiziuoe farmaceptias seo i'asa secondo lo claim 1, cgmprcsSeneaalmenu uo settore farmecuuticamente accettable.
4. Composition -armacaurica for nsosesondolu riaeudicazione 1, in which said principles are soeo comereui ie dotts composition in the following oapeorto, io pesk: R-kmtorolac between 0.3bU, BamePopide between 0.3 and 1, Acido eiflamian i.
5. Composiuione tarmacauth-a peo nsosesondolu riaeudicazione 3, in cui detti principitrivi soeo comereui ie dots composizione nel seguinte ospeorte: R-0e-oroiac1 s Bumetanide 1i Acido nifiumico 1.
6. Method for selecting, among a population of subjects affected by glioblastoma, a subpopulation of patients with therapy-related events, said method includes: - Measurement of the amount of expression of the LRRC8A VRAC channel subunit in GSC in the tumor of a given subject; - Measurement, in GSC, of the amount of expression of the LRRC8C VRAC channel subunit; - Celcala iel roparto del OveOc Sì sspressione di LRRC8A / LRRC8C, in eui, qooceodetterrazione su ugeule o aasuasreu 2^, said subject is a subject corresponding to the ietarasia, eotta teuapla consisting in the egmpooisionn tarmaoeutice for use according to claim 1.